Clinical Guidelines

4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD

Phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients

  • By

  • February 18, 2026

  • 2 min

Share

  • 1

    4FRONT-1 trial for wet age-related macular degeneration is completed.

  • 2

    Trial involved over 100 North American sites.

  • 3

    Patients received 4D-150 vs. aflibercept.

  • 4

    Primary endpoint: visual acuity change at 52 weeks.

  • 5

    Secondary endpoint: treatment burden reduction.

  • 6

    Top-line data expected first half of

  • 7

    4D-150 utilizes adeno-associated virus vector.

  • 8

    Broader program includes 4FRONT-2 trial enrolling globally.

Original Source(s)

4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD

Phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients

  • February 18, 2026

  • 2 min

Related Content

Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Patterns of Spread in Ocular Melanoma

Study examines lymphatic and distant metastasis risk

A New Route for RGC Survival?

Vascularizing retinal organoids offers new possibilities for preserving retinal ganglion cells inside organoids

  • February 18, 2026

  • 2 min